Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomized controlled trial: a systematic review of published responses

Author:

Williams Norman R1ORCID,Patrick Hannah2ORCID,Fiorentino Francesca3,Allen Alexander4,Sharma Manuj5,Milošević Mišel6,Macbeth Fergus7ORCID,Treasure Tom8ORCID

Affiliation:

1. Surgical and Interventional Trials Unit, University College London , London, UK

2. South London Healthcare NHS Trust , London, UK

3. Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's Clinical Trials Unit, Kings College London , London, UK

4. Royal Free London NHS Foundation Trust , London, UK

5. Research Department of Primary Care and Population Health, University College , London, UK

6. Thoracic Surgery Clinic, Institute for Lung Diseases of Vojvodina , Sremska Kamenica, Serbia

7. Centre for Trials Research, Cardiff University , Cardiff, UK

8. Clinical Operational Research Unit, University College London , London, UK

Abstract

Abstract OBJECTIVES The objective of this review was to assess the nature and tone of the published responses to the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) randomized controlled trial. METHODS Published articles that cited the PulMiCC trial were identified from Clarivate Web of Science (©. Duplicates and self-citations were excluded and relevant text was extracted. Four independent researchers rated the extracts independently using agreed scales for the representativeness of trial data and the textual tone. The ratings were aggregated and summarized. Two PulMiCC authors carried out a thematic analysis of the extracts. RESULTS Sixty-four citations were identified and relevant text was extracted and examined. The consensus rating for data inclusion was a median of 0.25 out of 6 (range 0–5.25, interquartile range 0–1.5) and, for textual tone, the median rating was 1.87 out of 6 (range 0–5.75, interquartile range 1–3.5). The majority of citations did not provide adequate representation of the PulMiCC data and the overall textual tone was dismissive. Although some were supportive, many discounted the findings because the trial closed early and was underpowered to show non-inferiority. Two misinterpreted the authors’ conclusions but there was an acceptance that 5-year survival was much higher than widely assumed. CONCLUSIONS Published comments reveal a widespread reluctance to consider seriously the results of a carefully conducted randomized trial. This may be because the results challenge accepted practice because of ‘motivated reasoning’, but there is a widespread misunderstanding of the fact that though PulMiCC with 93 patients was underpowered to test non-inferiority, it still provides reliable evidence to undermine the widespread belief in a major survival benefit from metastasectomy.

Funder

Cancer Research UK

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,General Medicine,Surgery

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Reply to Gkikas et al.;European Journal of Cardio-Thoracic Surgery;2023-05-25

2. Current status and novel insights into the role of metastasectomy in the era of immunotherapy;Expert Review of Anticancer Therapy;2022-12-22

3. Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy?;Journal of Thoracic Disease;2022-11

4. The cohort data in the full pulmonary metastasectomy in colorectal cancer study: Comment on Engstrand et al;European Journal of Surgical Oncology;2022-08

5. Pulmonary metastasectomy: the discussion continues;European Journal of Cardio-Thoracic Surgery;2022-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3